FindTrial
Sign In

To predict the ICSI outcome based on the combined morphological abnormalities of gametes

ICSI Outcome Based on Multiple Morphological Defects of Gametes - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056198
Enrollment
25
Registered
2023-08-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z319- Encounter for procreative management, unspecified

Interventions

Intervention1: Antag cetrorelix : Antag cetrorelix acetate injection will be added when two to three follicles reached 14 to 16 mm Intervention2: Recombinant HCG 250 mg and Decapeptyl 0.2 mg: Recom

Sponsors

A4 Hospital and Maternity Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Maternal age M2 >4. Sperm count > 1 million/ml. ICSI cycles. Self cycles with follicular phase stimulation. Only blast culture. Only antagonist cycle. No add on techniques. Density gradient method for sperm preparation. SDI calculation by Lenshook CASA method on the ICSI day. Freshly ejaculated semen sample.

Exclusion criteria

Exclusion criteria: Sperm count Donor egg program. Donor sperm program. Surgically retrieved sperms. Ivf cycles. Endometriosis. Endometrium Thickness Day 3 embryos for ET. Difficult ET. Retained Embryos during ET. Add on techniques for Sperm, ICSI, ET. Luteal phase stimulation.

Design outcomes

Primary

MeasureTime frame
Blastocyst rate & Grade of blastocyst  Timepoint: Baseline—

Secondary

MeasureTime frame
Live birth rate & Miscarriage rate Timepoint: 9 months—

Countries

India

Contacts

Public ContactMr Rajesh Kumar Anandaraj

A4 Hospital and Maternity Centre

rukmangatharaj@gmail.com9704555302

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026